ClinicalTrials.gg

Program

paxalisib

Also written as “SVG103”, “Paxalisib (GDC-0084)” and “[14C]-Paxalisib Capsule”.

Its studies are mostly in Glioblastoma · Tuberous Sclerosis, led by 3 companies.

Furthest: phase 2, since Mar 20, 20184 company-led studies, 1 open or runningNext primary completion: Feb 2027 (phase 2)

Who develops it

Each company that leads studies of it, as its sponsor page counts them.

CompanyStudies it leadsFurthest phaseFirst studyNext primary completion
Kazia Therapeutics20 open or runningphase 2since Mar 20, 2018Mar 20, 2018none ahead
Hoffmann-La Roche10 open or runningphase 1since Mar 5, 2012Mar 5, 2012none ahead
Sovargen11 open or runningphase 2since Dec 11, 2025Dec 11, 2025Feb 2027phase 2 · NCT07287202

Also a collaborator on its studies: quotient-sciences.

How these companies relate is not in the registry. A license or acquisition is shown only with a dated source, such as a company release or filing.

History and what’s ahead

From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.

  1. Mar 5, 2012First study: phase 1 study in GlioblastomaNew to Hoffmann-La RocheHoffmann-La Roche · NCT01547546 · 29 enrolled · United States, Spain
  2. Mar 20, 2018Kazia Therapeutics's first study: phase 2 study in GlioblastomaNew to Kazia TherapeuticsKazia Therapeutics · NCT03522298 · 30 enrolled · United States
  3. Aug 4, 2021Phase 1 study in HealthyKazia Therapeutics · NCT05012670 · 6 enrolled · United Kingdom
  4. Dec 11, 2025Sovargen's first study: phase 2 study in Focal Cortical DysplasiaNew to SovargenSovargen · NCT07287202 · 12 planned · Australia

Ahead

  1. Feb 2027Primary completion: phase 2 study in Focal Cortical DysplasiaSovargen · NCT07287202

TargetBeta

“PI3-kinase class I inhibitor”ChEMBL 37, by rule

Other programs on the same 8 targets

ProgramCompanyFurthest phaseStudies
gedatolisibrulePfizerphase 39

Studies

All 4 led by companies developing it, newest first. Each opens its study page.

StudyPhaseStatusLed byPrimary completionSize
NCT07287202Focal Cortical Dysplasia · Australia2RecruitingSovargenFeb 202712
NCT05012670Healthy · United Kingdom1CompletedKazia TherapeuticsMar 30, 20236
NCT03522298Glioblastoma · United States2CompletedKazia TherapeuticsMar 30, 202330
NCT01547546Glioblastoma · United States, Spain1CompletedHoffmann-La RocheJan 201529

How it is read

Names in the registry

  • “SVG103”, 1 entry
  • “Paxalisib (GDC-0084)”, 1 entry
  • “[14C]-Paxalisib Capsule”, 1 entry
  • “GDC-0084”, 1 entry

Conditions, from the studies’ own filings

First seen by our ledger Nov 13, 2026.

What this can’t show

  • Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
  • Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
  • Primary completion dates are the sponsors’ estimates and often move.
  • A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.